Cargando…

Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?

Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking...

Descripción completa

Detalles Bibliográficos
Autores principales: Markiewicz-Gospodarek, Agnieszka, Kuszta, Piotr, Baj, Jacek, Dobrowolska, Beata, Markiewicz, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087177/
https://www.ncbi.nlm.nih.gov/pubmed/35558538
http://dx.doi.org/10.3389/fpubh.2022.872430
_version_ 1784704146086035456
author Markiewicz-Gospodarek, Agnieszka
Kuszta, Piotr
Baj, Jacek
Dobrowolska, Beata
Markiewicz, Renata
author_facet Markiewicz-Gospodarek, Agnieszka
Kuszta, Piotr
Baj, Jacek
Dobrowolska, Beata
Markiewicz, Renata
author_sort Markiewicz-Gospodarek, Agnieszka
collection PubMed
description Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking food, and the proliferation of new adipocytes in the setting of obesity. So far, current research of NPS is only limited to animal models; data regarding its functions in humans is still scarce. Animal studies showed that anxiety and appetite might be suppressed by the action of NPS. The discovery of this neuromodulator peptide is effective considering its strong anxiolytic action, which has the potential to be an interesting therapeutic option in treating neuropsychiatric disorders. In this article, we aimed to analyze the pharmaceutical properties of NPS as well as its influence on several neurophysiological aspects—modulation of behavior, association with obesity, as well as its potential application in rehabilitation and treatment of psychiatric disorders.
format Online
Article
Text
id pubmed-9087177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90871772022-05-11 Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? Markiewicz-Gospodarek, Agnieszka Kuszta, Piotr Baj, Jacek Dobrowolska, Beata Markiewicz, Renata Front Public Health Public Health Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking food, and the proliferation of new adipocytes in the setting of obesity. So far, current research of NPS is only limited to animal models; data regarding its functions in humans is still scarce. Animal studies showed that anxiety and appetite might be suppressed by the action of NPS. The discovery of this neuromodulator peptide is effective considering its strong anxiolytic action, which has the potential to be an interesting therapeutic option in treating neuropsychiatric disorders. In this article, we aimed to analyze the pharmaceutical properties of NPS as well as its influence on several neurophysiological aspects—modulation of behavior, association with obesity, as well as its potential application in rehabilitation and treatment of psychiatric disorders. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9087177/ /pubmed/35558538 http://dx.doi.org/10.3389/fpubh.2022.872430 Text en Copyright © 2022 Markiewicz-Gospodarek, Kuszta, Baj, Dobrowolska and Markiewicz. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Markiewicz-Gospodarek, Agnieszka
Kuszta, Piotr
Baj, Jacek
Dobrowolska, Beata
Markiewicz, Renata
Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
title Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
title_full Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
title_fullStr Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
title_full_unstemmed Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
title_short Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?
title_sort can neuropeptide s be an indicator for assessing anxiety in psychiatric disorders?
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087177/
https://www.ncbi.nlm.nih.gov/pubmed/35558538
http://dx.doi.org/10.3389/fpubh.2022.872430
work_keys_str_mv AT markiewiczgospodarekagnieszka canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders
AT kusztapiotr canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders
AT bajjacek canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders
AT dobrowolskabeata canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders
AT markiewiczrenata canneuropeptidesbeanindicatorforassessinganxietyinpsychiatricdisorders